Synovial Sarcoma in Children, Adolescents, and Young Adults: A Report from the Children's Oncology Group ARST0332 Study

Rajkumar Venkatramani, Wei Xue, R. Lor Randall, Suzanne Wolden, James Anderson, Dolores Lopez-Terrada, Jennifer Black, Simon C. Kao, Barry Shulkin, Andrew Ostrenga, Alberto Pappo, Sheri L. Spunt

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

PURPOSE Synovial sarcoma (SS) is the second most common malignant soft tissue tumor in children. ARST0332 evaluated a risk-based treatment strategy for young patients with soft tissue sarcoma designed to limit therapy for low-risk (LR) disease and to test neoadjuvant chemoradiotherapy for unresected higher-risk disease. METHODS Newly diagnosed patients with SS age , 30 years were assigned to four treatment arms based on disease features: A (surgery only), B (55.8 Gy radiotherapy [RT]), C (ifosfamide and doxorubicin [ID] chemotherapy plus 55.8 Gy RT), and D (neoadjuvant ID and 45 Gy RT, then surgery and RT boost based on margins followed by adjuvant ID). Patients treated in Arms A and B were considered LR, arms C and D without metastases as intermediate-risk (IR), and those with metastases as high-risk (HR). RESULTS Of the 146 patients with SS enrolled, 138 were eligible and evaluable: LR (46), IR (71), and HR (21). Tumors were 80% extremity, 70% . 5 cm, 70% high-grade, 62% invasive, 95% deep, and 15% metastatic. Treatment was on arm A (29.7%), B (3.6%), C (16.7%), and D (50%). There were no toxic deaths and four unexpected grade 4 adverse events. By risk group, at a median follow-up of 6.8 years, estimated 5-year eventfree survival was LR 82%, IR 70%, and HR 8%, and overall survival was LR 98%, IR 89%, and HR 13%. After accounting for the features that defined risk category, none of the other patient or disease characteristics (age, sex, tumor site, tumor invasiveness, and depth) improved the risk stratification model. CONCLUSION The risk-based treatment strategy used in ARST0332 produced favorable outcomes in patients with nonmetastatic SS relative to historical controls despite using RT less frequently and at lower doses. The outcome for metastatic SS remains unsatisfactory and new therapies are urgently needed.

Original languageEnglish (US)
Pages (from-to)3927-3937
Number of pages11
JournalJournal of Clinical Oncology
Volume39
Issue number35
DOIs
StatePublished - Dec 10 2021

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Synovial Sarcoma in Children, Adolescents, and Young Adults: A Report from the Children's Oncology Group ARST0332 Study'. Together they form a unique fingerprint.

Cite this